Organization | Benazir Bhutto Hospital, Rawalpindi

Benazir Bhutto Hospital, Rawalpindi Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2013

NCT02212392

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Benazir Bhutto Hospital, Rawalpindi | Departemt of Pharmacy,Shaheed Benazir Bhutto University,Sheringal Dir Upper,KP,Pakistan

Active Ingredients

Drugs in Phase 2 Trials (1)

meropenem (merrem) (1 trial)

Drugs in Phase 1 Trials (4)

gemifloxacin (factive) (1 trial)

ibuprofen (motrin) (1 trial)

ketorolac (acuvail) (3 trials)

moxifloxacin (avelox) (1 trial)

Drugs in Other Trials (6)

atracurium (tracurium) (2 trials)

cefuroxime (zinacef) (2 trials)

midazolam (versed) (2 trials)

propofol (diprivan) (2 trials)

ranitidine (zantac) (2 trials)

sevoflurane (ultane) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Pancreatitis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 11